Ifinatamab Deruxtecan

Antibody–drug conjugate

Also known as MK-2400

Phase 3underway

Evidence outlook · registrational

Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-01-30. The sponsor reported topline results of a Phase 2 study on 2025-09-07 (IDeate-Lung01 (NCT05280470) Phase 2: confirmed objective response rate 48.2% in 137 previously treated ES-SCLC patients); that is not the registrational readout.

Also in development:Non-Small Cell Lung Cancer · Phase 2Metastatic Castration-Resistant Prostate Cancer · Phase 3Esophageal Squamous Cell Carcinoma · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Esophageal Squamous Cell Carcinoma
Small Cell Lung Cancer
Other / comorbidity
Phase 2 (4)
Non-Small Cell Lung Cancer
NCT06780085 · Merck Sharp & Dohme LLC
2025-05-13 – 2032-03-12 · Carcinoma, Non-Small-Cell Lung
What this study did
Small Cell Lung Cancer
Other / comorbidity
NCT07925268 · Rahul Aggarwal
2026-11-07 – 2031-11-30 · Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer
What this study did
Phase 1/2 (11)
Esophageal Squamous Cell Carcinoma
NCT06780111 · Merck Sharp & Dohme LLC
2025-07-30 – 2032-01-04 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07405151 · Merck Sharp & Dohme LLC
2026-03-27 – 2028-06-12 · Oesophageal Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT07227597 · Merck Sharp & Dohme LLC
2026-01-29 – 2030-12-30 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT04471727 · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2020-12-14 – 2028-01-28 · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did
Other / comorbidity
NCT06863272 · Merck Sharp & Dohme LLC
2025-07-03 – 2031-10-01 · Castration-Resistant Prostatic Cancer, Metastasis
What this study did
NCT07630974 · Merck Sharp & Dohme LLC
2026-07-06 – 2031-08-17 · Malignant Neoplasm
What this study did
NCT04145622 · Daiichi Sankyo
2019-11-03 – 2029-10-31 · Advanced Solid Tumor, Malignant Solid Tumor
What this study did
NCT06330064 · Daiichi Sankyo
2024-04-10 – 2028-07-25 · Recurrent or Metastatic Solid Tumors
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ifinatamab Deruxtecan: this drugPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590).
NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181).
TislelizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(17 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ifinatamab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
Phase 1/2Advanced Solid Tumor, Malignant Solid TumorActive not recruiting
Est. primary completion 2027-04-30 · NCT04145622 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-12 · NCT07405151 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-20 · NCT06362252 · CT.gov ↗
What to watch
2028 (6)
January 2028 (2)
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-30 · NCT06203210 · CT.gov ↗
What to watch
June 2028 (2)
Phase 3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT06644781 · CT.gov ↗
What to watch
Phase 3Prostate Cancer, Prostatic NeoplasmsRecruiting
Est. primary completion 2028-06-26 · NCT06925737 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2Recurrent or Metastatic Solid TumorsRecruiting
Est. primary completion 2028-07-25 · NCT06330064 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT07925268 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-15 · NCT06780137 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
2031 (2)
August 2031 (1)
Phase 1/2Malignant NeoplasmRecruiting
Est. primary completion 2031-08-17 · NCT07630974 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1/2Castration-Resistant Prostatic Cancer, MetastasisRecruiting
Est. primary completion 2031-10-01 · NCT06863272 · CT.gov ↗
What to watch
2032 (4)
January 2032 (1)
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch
March 2032 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-03-02 · NCT06780098 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-03-12 · NCT06780085 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 September 2026WithdrawalUS BLA for ifinatamab deruxtecan in pretreated ES-SCLC voluntarily withdrawn
US, FDA · Daiichi Sankyo · Source ↗
7 September 2025Topline resultIDeate-Lung01 (NCT05280470) Phase 2: confirmed objective response rate 48.2% in 137 previously treated ES-SCLC patients